Leukoencephalopathy

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Retrieved on: 
Wednesday, January 3, 2024
Leukoencephalopathy, Senior counsel, Conference, European Commission, Food, MRI, Medicine, IND, CSF1R, FDA, Civil service commission, Clinical trial, Investigational New Drug, IGNITE, TREM2, AFL, CNS, SAD, Neurodegenerative disease, Biomarker, Pathology, Completeness, Genetic testing, Patient, Diagnosis, Safety, Microglia, Magnetic resonance imaging, Pharmaceutical industry

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today provided a 2023 year-in-review and outlined key milestones anticipated in 2024. The Company also today announced that it has extended its projected cash runway into the second half of 2025.

Key Points: 
  • ET -
    WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today provided a 2023 year-in-review and outlined key milestones anticipated in 2024.
  • “2023 marked a year of persistent advancement and landmark achievements for the Company,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “Most notably, we were the first company to demonstrate clinical data supporting TREM2 agonism as a potential therapeutic approach in neurodegenerative disease.
  • “We enter 2024 well-positioned to achieve our planned value-driving milestones across our development pipeline,” concluded Dr. Magovčević-Liebisch.

Bank of Charles Town Receives 2022 FHLBank Pittsburgh Diversity, Equity and Inclusion Membership Award; Group Tours Facility of Banking On Diversity Funding Recipient

Retrieved on: 
Wednesday, November 30, 2022
Professional Services, DEI (Diversity, Equity and Inclusion), Environmental, Social and Governance (ESG), Small Business, Socially Responsible Investing, Finance, Banking, Black History Month, Housing, OTC, Financial management, Federal Home Loan Banks, Economic development, Multimedia, Insurance, Trust, Bank, Community, PTBS, Virtual reality, USN, Small business, Shenandoah, BCT, American Banker, Family, Harpers Ferry, West Virginia, Community banking models, Congress, Autism, Equity, Award, USMC, DEI, Management, Leukoencephalopathy

Today, the Federal Home Loan Bank of Pittsburgh (FHLBank) announced that Bank of Charles Town (BCT) received the inaugural 2022 FHLBank Diversity, Equity and Inclusion (DEI) Membership Award (Award) for their Banking On Diversity program.

Key Points: 
  • Today, the Federal Home Loan Bank of Pittsburgh (FHLBank) announced that Bank of Charles Town (BCT) received the inaugural 2022 FHLBank Diversity, Equity and Inclusion (DEI) Membership Award (Award) for their Banking On Diversity program.
  • It was difficult to select a winner from among such dynamic programs and initiatives, said Katey Malesic, FHLBanks Chief Diversity, Equity and Inclusion Officer.
  • BCTs collaborative Banking On Diversity program, which provides early-stage, interest-free capital to both start-up and existing micro-businesses stood out as having unique community impact.
  • Along with two other neighboring community banks, the innovative Banking On Diversity, Minority Business Loan Fund was created.

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, GLOBE, SEC, Brain, Board, Security (finance), Annual report, Marketing, Patient, Neurodegeneration, Board of directors, EAN, Food, CNS, ALSP, Diagnosis, Congress, CSF1R, Publication, Report, Nasdaq, Conference, Investigational New Drug, Systematic review, Forward-looking statement, European Academy of Management, Growth, Microglia, Poster, Incidence, CALD, COVID-19, D, Program, AD, Food and Drug Administration, FDA, Leukoencephalopathy, AAIC, Company, Therapy, Research, Approximation error, TREM2, IPO, Pharmaceutical industry, Macrophage, IND

This designation provides the potential to obtain certain benefits, including financial incentives to support clinical development and seven years of marketing exclusivity upon FDA approval.

Key Points: 
  • This designation provides the potential to obtain certain benefits, including financial incentives to support clinical development and seven years of marketing exclusivity upon FDA approval.
  • This strategic prioritization is expected to extend the Companys cash runway through the end of the second quarter of 2024.
  • The Company expects its cash and cash equivalents to fund its operational plans through the end of the second quarter of 2024.
  • Net Loss: Loss from operations for the second quarter ended June 30, 2022, were $17.0 million, compared to $11.4 million for the same period in 2021.

Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022

Retrieved on: 
Monday, August 1, 2022
Death, AAIC, Brain, Diagnosis, IPO, GLOBE, Awareness, Physician, Cell death, ALSP, U.S. Securities and Exchange Commission, TREM2, Microglia, Neurodegeneration, Forward-looking statement, SEC, Publication, Frontotemporal dementia, COVID-19, Approximation error, Alzheimer's disease, Conference, HIV disease progression rates, Disease, FDA, SD, CSF1R, Security (finance), Patient, Genetic testing, Nasdaq, Leukoencephalopathy, Annual report, SYK, Phosphorylation, Report, Pharmaceutical industry, Marketing, Vaccine, Macrophage

Importantly, ALSP is commonly misdiagnosed as a neurodegenerative dementia and in the presence of family history and radiological findings physicians should consider genetic testing for ALSP.

Key Points: 
  • Importantly, ALSP is commonly misdiagnosed as a neurodegenerative dementia and in the presence of family history and radiological findings physicians should consider genetic testing for ALSP.
  • VGL101 administration induced phosphorylation of SYK in both hMDM and iMGL models, demonstrating agonism of the TREM2 receptor.
  • Increases in soluble CSF1R and decreases in soluble TREM2 upon VGL101 administration in iMGLs may inform target engagement studies.
  • The findings of this study supported and expanded the previous, smaller case reports on the phenotypic characteristics of ALSP.

New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio

Retrieved on: 
Thursday, April 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Other Health, Brain disorders, Rare diseases, Monoclonal antibodies, Medical specialties, Branches of biology, Clinical medicine, Progressive multifocal leukoencephalopathy, Ocrelizumab, PML, Leukoencephalopathy, spinal muscular atrophy, Evrysdi™ (risdiplam), multiple sclerosis, Ocrevus, neuromyelitis optica spectrum disorder, Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Key Points: 
  • If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
  • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
  • Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.
  • These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.

Progressive Multifocal Leukoencephalopathy Pipeline Review, H2 2020 Report - Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Development Milestones, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 12, 2021
Health, Pharmaceutical, Brain disorders, Leukoencephalopathy, Medical specialties, Branches of biology, Progressive multifocal leukoencephalopathy, Clinical medicine, PMLE

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Health, Infectious diseases, Pharmaceutical, Brain disorders, Leukoencephalopathy, Progressive multifocal leukoencephalopathy, Pipeline, Branches of biology, Medical specialties, Medicine

The "Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progressive Multifocal Leukoencephalopathy development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report covers pipeline activity across the complete product development cycle i.e.

Global Market Study on Progressive Multifocal Leukoencephalopathy Treatment: HIV/AIDS Indication to Dominate in Terms of Value Through 2026 Owing to Government Initiatives and Support for HIV Associated PML Treatment

Retrieved on: 
Wednesday, September 26, 2018
Brain disorders, Medicine, Progressive multifocal leukoencephalopathy, JC virus, Microbiology, Leukoencephalopathy, Multiple sclerosis, Immunology

The Progressive Multifocal Leukoencephalopathy Treatment Market is Segmented Based on:

Key Points: 
  • The Progressive Multifocal Leukoencephalopathy Treatment Market is Segmented Based on:
    This report covers the global progressive multifocal leukoencephalopathy treatment market performance in terms of revenue contribution from various segments.The global progressive multifocal leukoencephalopathy treatment market report begins with an overview and definitions.
  • This is then followed by the key drivers, restraints and trends of the global progressive multifocal leukoencephalopathy treatment market.
  • The global progressive multifocal leukoencephalopathy treatment market is segmented based on drug type, indication, distribution channel and regions.Based on drug type, the global progressive multifocal leukoencephalopathy treatment market is segmented into anti-retroviral therapy, antiviral/anti JCV and other symptomatic.
  • Based on indication, the global progressive multifocal leukoencephalopathy treatment market is segmented into HIV/AIDS, organ transplantation, multiple sclerosis and hematological malignancies.Based on distribution channel, the global progressive multifocal leukoencephalopathy treatment market is segmented into hospital pharmacies, drug stores and retail pharmacies.

Progressive Multifocal Leukoencephalopathy Treatment Market to Reach a Valuation of US$ 150.5 Mn by 2026 - Persistence Market Research

Retrieved on: 
Wednesday, September 5, 2018
Brain disorders, Progressive multifocal leukoencephalopathy, JC virus, Medicine, Leukoencephalopathy, Microbiology, Immunology

The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026.

Key Points: 
  • The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026.
  • Anti-retroviral therapy, Anti JCV, and other symptomatic drugs for progressive multifocal leukoencephalopathy treatment are available in the market.
  • Symptomatic treatment of progressive multifocal leukoencephalopathy is projected to hold +32% market share in 2018, with significant revenue contribution to the global progressive multifocal leukoencephalopathy treatment market.
  • Use of antiretroviral therapy for HIV-infected patients is expected to boost the global progressive multifocal leukoencephalopathy treatment market.

Progressive Multifocal Leukoencephalopathy Treatment Market to Reach a Valuation of US$ 150.5 Mn by 2026 - Persistence Market Research

Retrieved on: 
Wednesday, August 29, 2018
Brain disorders, Progressive multifocal leukoencephalopathy, JC virus, Medicine, Leukoencephalopathy, Microbiology, Immunology

The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026.

Key Points: 
  • The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026.
  • Anti-retroviral therapy, Anti JCV, and other symptomatic drugs for progressive multifocal leukoencephalopathy treatment are available in the market.
  • Symptomatic treatment of progressive multifocal leukoencephalopathy is projected to hold +32% market share in 2018, with significant revenue contribution to the global progressive multifocal leukoencephalopathy treatment market.
  • Use of antiretroviral therapy for HIV-infected patients is expected to boost the global progressive multifocal leukoencephalopathy treatment market.